Novartis Investigative Site

Hefei, Anhui 230601

3 studies enrolling now · 11 studies all time

What they study most

Autoimmunity, Inflammation, Generalized Myasthenia Gravis, IgA Nephropathy, Immunoglobulin A Nephropathy, Neoplasms, Gastrointestinal Tract, Non-Small Cell Lung Cancer, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis (PMF), Sjogren Syndrome, Sjogrens Syndrome, Sjögren Syndrome

Studies at this site

• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) — Recruiting now
• Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Recruiting now
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss — Stopped early
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Running, not enrolling
• A Study of Zigakibart in Adults With IgA Nephropathy — Running, not enrolling
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome — Stopped early